Page last updated: 2024-09-02

hydroxyitraconazole and Angiogenesis, Pathologic

hydroxyitraconazole has been researched along with Angiogenesis, Pathologic in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Ahn, C; Brekken, RA; Chembukar, V; DeBerardinis, RJ; Do, QN; Fattah, FJ; Faubert, B; Gerber, DE; Kallem, RR; Kasiri, S; Kernstine, KH; Kim, J; Leff, RD; Lenkinski, RE; Padmanabhan, C; Pedrosa, I; Pelosof, L; Putnam, WC; Reznik, SI; Saltarski, JM; Skelton, R; Subramaniyan, I; Xi, Y; Yuan, Q1

Trials

1 trial(s) available for hydroxyitraconazole and Angiogenesis, Pathologic

ArticleYear
Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 11-15, Volume: 26, Issue:22

    Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Female; Hedgehog Proteins; Humans; Itraconazole; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Patched-1 Receptor; Zinc Finger Protein GLI1

2020